Meet Our Senior Advisors
CEO and Director, Phoenix Biotech Acquisition Corp
Chris Ehrlich is CEO and a Director of Phoenix Biotech Acquisition Corp, a $175M blank check company focused on biotech. Prior to PBAC, Chris was CEO and a Director of Locust Walk Acquisition Corp, a $175M blank check company that merged with eFFECTOR Therapeutics in August 2021. Chris was a Managing Director at Locust Walk for eight years, leading the strategic transactions efforts. Prior to joining Locust Walk in 2013, Mr. Ehrlich served as a Managing Director at InterWest Partners, a venture capital firm focused on healthcare and information technology, from 2000 to 2013. At InterWest, he served on the boards of KAI Pharmaceuticals (acquired by Amgen in 2012), Biomimetic Therapeutics (acquired by Wright Medical Technologies in 2013), Invuity (acquired by Stryker in 2018) and Xenon Pharmaceuticals (NASDAQ: XENE). Prior to joining InterWest, Mr. Ehrlich was a Director of Licensing and Business Development at Purdue Pharma. Prior to joining Purdue, Mr. Ehrlich worked in business development at Genentech, in venture capital at the U.S. Russia Investment Fund, and in biotechnology strategy development at L.E.K. Consulting. Since 2014, Mr. Ehrlich has served on the Board of Directors of Prostate Management Diagnostics, on the Advisory Board of the Peter Michael Foundation, a charity focused on prostate cancer where he has been a Senior Advisor since 2012, and on the Healthcare at Kellogg Advisory Board at Northwestern University since 2019. He received his undergraduate degree from Dartmouth College and a MBA from the Kellogg School of Management at Northwestern University.